The U.S. Food and Drug Administration has extended the expiry date of certain lots of EpiPens for up to four months in order to combat intermittent supply interruptions of the allergy injectors during back-to-school season.
This decision was made based on stability data provided by Pfizer and reviewed by the FDA. The specific batches can be seen here. Patients that have EpiPens from these batches are able to use them through the corresponding new use dates.
FDA is not requiring or recommending that the identified batches in the following tables be relabeled with their new use dates.
The supply shortage has been caused by manufacturing issues at the Pfizer plant which supplies EpiPens.
Read the full FDA statement